Clinical Trial

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Study acronym: JOURNEY
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2025-03-12; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Recruiting 2025-03-31
Trial Details
NCT Number NCT06878261
Lead Sponsor AstraZeneca
Collaborators: Amgen
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 990 participants
Start Date 2025-03-25
Primary Completion 2029-03-13 (estimated)
Study Completion 2029-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-24